HOME >> BIOLOGY >> NEWS
Mapping genes for schizophrenia in the South Pacific

ARTICLE: "Genome-wide multipoint linkage analyses of multiplex schizophrenia pedigrees from the oceanic nation of Palau"

AUTHORS: B. Devlin, Silviu-Alin Bacanu, Kathryn Roeder, Fred Reimherr, Paul Wender, Brandi Galke, Denise Novasad, Allan Chu, Karen T.Cuenco, Seba Tiobek, Caleb Otto, William Byerley

Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA; Department of Statistics, Carnegie Mellon University, Pittsburgh, PA; Department of Psychiatry, University of Utah Medical Center, Salt Lake City, Utah; Department of Psychiatry, University of California, Irvine, CA; Department of Genetics, University of Pittsburgh, Pittsburgh, PA; Belau National Hospital, Korror, Palau.

Schizophrenia is a devastating neuropsychiatric disorder that afflicts 1% of the worldwide population. Remarkably, the prevalence of schizophrenia is the same throughout the world despite differing cultures and environments of most nations. It is also notable that the cardinal signs and symptoms of schizophrenia - hallucinations and delusions - are the same throughout the world. In addition, family, twin and adoption studies from different populations indicate genetic factors contribute substantially to susceptibility to this illness. Small, isolated populations can be useful for gene mapping for two reasons: the genetic causes of illness are typically less heterogeneous, and isolated populations often contain large extended multiplex pedigrees ideal for mapping genes. For these reasons, the investigators initiated a genetic study of schizophrenia in Palau, Micronesia. Palau, also termed Belau, which is located approximately 725 miles southwest of Guam in the South Pacific. Presentation and symptoms of schizophrenia are no different in Palau.

The study findings, published in the September issue of Molecular Psychiatry, indicate that the genetic factors are distinct for each of the 5 families. The findings were perhaps somewhat unexpecte
'"/>

Contact: Frank Sissingh
molecularpsychiatry@mednet.ucla.edu
310-206-6739
Molecular Psychiatry
3-Sep-2002


Page: 1 2

Related biology news :

1. Mapping the evolution of a virus
2. Organization for Human Brain Mapping 2004 Annual Meeting
3. Mapping a road to understanding human health
4. Organization for Human Brain Mapping annual meeting abstract highlights
5. Organization for Human Brain Mapping 2003 Annual Meeting
6. Mapping proteins
7. Elementary Students Mapping Virginia Wildlife
8. Rare Brain Mapping Procedure Provides Unique Picture Of Two Areas Concerned With Language Processing and Production
9. Subterranean Mapping Method Will Find Homes For Pollution-Eating Bacteria
10. Mapping The Way To A Bigger Prawn
11. Brain Mapping In Real Time

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Mapping genes for schizophrenia the South Pacific

(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) — ... online medical bill review and advocacy service, has signed ... FREE WellCard Savings discount health services marketplace. ... was more than they expected to pay. As part ... care costs, WellCard Savings is pleased to offer medical ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
Cached News: